Plus Therapeutics, Inc. (PSTV) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Sonoma Pharmaceuticals, Inc.

Plus Therapeutics, Inc.

Palisade Bio, Inc.

ABVC BioPharma, Inc.

Synaptogenix, Inc.

Tempest Therapeutics, Inc.

ZyVersa Therapeutics, Inc.

Petros Pharmaceuticals, Inc.

Panbela Therapeutics, Inc.

Aptorum Group Ltd.

Universe Pharmaceuticals, Inc.

Why is Plus Therapeutics, Inc. ?

Poor Management Efficiency with a low ROE of 0%

The company has reported losses. Due to this company has reported negative ROE

Poor long term growth as Net Sales has grown by an annual rate of 42.67% over the last 5 years

Flat results in Mar 26

OPERATING CASH FLOW(Y) Lowest at USD -20.85 MM
PRE-TAX PROFIT(Q) At USD -6.95 MM has Fallen at -40.64%
NET SALES(Q) Lowest at USD 1.03 MM

Risky -

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of -17.04%, its profits have fallen by -27.3%

Consistent Underperformance against the benchmark over the last 3 years

Along with generating -17.04% returns in the last 1 year, the stock has also underperformed S&P 500 in each of the last 3 annual periods

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Plus Therapeutics, Inc. for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

Plus Therapeutics, Inc.

-17.04%

0.04

2063.16%

S&P 500

25.41%

1.92

13.25%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

42.67%

EBIT Growth (5y)

-16.62%

EBIT to Interest (avg)

-9.96

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

0.42

Sales to Capital Employed (avg)

-0.49

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

9.69%

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

9.89

EV to EBIT

-1.78

EV to EBITDA

-1.83

EV to Capital Employed

-3.27

EV to Sales

5.22

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-593.47%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Dow Theory

Bearish

OBV

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

4What is working for the Company

NET PROFIT(HY)

Higher at USD -12.66 MM

RAW MATERIAL COST(Y)

Fallen by -7.92% (YoY

-12What is not working for the Company

OPERATING CASH FLOW(Y)

Lowest at USD -20.85 MM

PRE-TAX PROFIT(Q)

At USD -6.95 MM has Fallen at -40.64%

NET SALES(Q)

Lowest at USD 1.03 MM

OPERATING PROFIT(Q)

Lowest at USD -7.01 MM

OPERATING PROFIT MARGIN(Q)

Lowest at -681.91 %

Here's what is working for Plus Therapeutics, Inc.

Net Profit

Higher at USD -12.66 MM

than preceding 12 month period ended Mar 2026

MOJO Watch

In the half year the company has already crossed Net Profit of the previous twelve months

Net Profit (USD MM)

Raw Material Cost

Fallen by -7.92% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Plus Therapeutics, Inc.

Net Sales

At USD 1.03 MM has Fallen at -21.12%

over average net sales of the previous four periods of USD 1.3 MM

MOJO Watch

Near term sales trend is extremely negative

Net Sales (USD MM)

Pre-Tax Profit

At USD -6.95 MM has Fallen at -40.64%

over average net sales of the previous four periods of USD -4.94 MM

MOJO Watch

Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (USD MM)

Operating Cash Flow

Lowest at USD -20.85 MM and Fallen

In each year in the last three years

MOJO Watch

The company's cash revenues from business operations are falling

Operating Cash Flows (USD MM)

Net Sales

Lowest at USD 1.03 MM

in the last five periods

MOJO Watch

Near term sales trend is negative

Net Sales (USD MM)

Operating Profit

Lowest at USD -7.01 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is negative

Operating Profit (USD MM)

Operating Profit Margin

Lowest at -681.91 %

in the last five periods

MOJO Watch

Company's profit margin has deteriorated

Operating Profit to Sales